Patents Examined by Kimberly Ballard
  • Patent number: 10421944
    Abstract: The composition for producing neural stem cells provided by the present invention contains an artificially synthesized synthetic peptide having a neural stem cell-inducing peptide sequence that induces neural stem cells from fibroblasts, and one or two or more pharmaceutically acceptable carriers. The neural stem cell-inducing peptide sequence is any of (i) an amino acid sequence constituting a signal peptide of any protein belonging to the amyloid precursor protein (APP) family, (ii) a partial amino acid sequence of the amino acid sequence of (i), and (iii) a modified amino acid sequence of the amino acid sequence of (i) or (ii).
    Type: Grant
    Filed: September 29, 2016
    Date of Patent: September 24, 2019
    Assignees: TOAGOSEI CO. LTD., KEIO UNIVERSITY
    Inventors: Nahoko Baileykobayashi, Kenichi Tanaka, Tetsuhiko Yoshida, Jun Kudo
  • Patent number: 10407495
    Abstract: The present invention relates to therapeutic agents comprising bispecific recombinant antibody fragments to selectively clear a protein associated with a neurological disease and methods of use of these therapeutic agents to treat neurological diseases.
    Type: Grant
    Filed: October 24, 2016
    Date of Patent: September 10, 2019
    Assignee: ARIZONA BOARD OF REGENTS, A BODY CORPORATE OF THE STATE OF ARIZONA, ACTING FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY
    Inventors: Michael Sierks, Yong Shen
  • Patent number: 10406180
    Abstract: The present invention relates to a composition including stem cell-derived microvesicles as an active ingredient for promoting neurogenesis. The stem cell-derived microvesicles according to the present invention can promote neurogenesis and migration of nerves and also promote angiogenesis in vascular endothelial cells, and thus can be usefully used in treatment of neurological damage.
    Type: Grant
    Filed: July 14, 2017
    Date of Patent: September 10, 2019
    Assignee: Samsung Life Public Welfare Foundation
    Inventors: Oh Young Bang, Gyeong Joon Moon, Yeon Hee Cho, Suk Jae Kim, Dong Hee Kim, Ji Hee Sung
  • Patent number: 10407465
    Abstract: The present invention relates to peptides enhancing neuronal outgrowth, particularly to peptides that enhance neurite outgrowth and their application.
    Type: Grant
    Filed: October 20, 2015
    Date of Patent: September 10, 2019
    Assignee: SCHWEITZER BIOTECH COMPANY LTD.
    Inventor: Ying-Chen Yang
  • Patent number: 10391149
    Abstract: The present application provides a composition and methods to enhance nerve regeneration utilizing at least one component of neural stem cells or IL12p40. The composition comprises neural stem cells and a neurotrophic factor, which is constructed by IL12p40 as at least one subunit. The methods to enhance nerve regeneration comprise providing a nerve regeneration composition comprising a neurotrophic factor containing IL12p40 as at least one subunit to a subject. The composition of the methods can further comprise neural stem cells.
    Type: Grant
    Filed: August 14, 2015
    Date of Patent: August 27, 2019
    Assignee: NATIONAL HEALTH RESEARCH INSTITUTES
    Inventors: Ing-Ming Chiu, Ya-Hui Chi, Don-Ching Lee
  • Patent number: 10385098
    Abstract: The present invention relates to spexin-based agonists specific for galanin receptor type 2 and use thereof. More specifically, the present invention provides peptide-based agonists with high specificity for galanin receptor type 2 and improved stability. The peptide-based agonists are involved in the regulation of in vivo physiological functions, such as food intake, anxiety, emotion, and addiction, for which galanin receptors type 2 is responsible, to effectively suppress appetite, help recover from anxiety disorder, and reduce pleasure addiction. Therefore, the peptide-based agonists can be used to prevent or treat galanin receptor type 2-mediated diseases.
    Type: Grant
    Filed: November 30, 2016
    Date of Patent: August 20, 2019
    Assignee: Neuracle Science Co., Ltd.
    Inventors: Jae Young Seong, Jong-Ik Hwang, Dong-Hoon Kim, Gi Hoon Son, Yoo-Na Lee, Seongsik Yun, Arfaxad Reyes-Alcaraz
  • Patent number: 10383887
    Abstract: The present invention is directed to a method of preventing or reducing amyloid deposition in a subject. This method involves selecting a subject with amyloid deposits and stimulating the innate immune system of the selected subject under conditions effective to reduce the amyloid deposits. Also disclosed is a method of preventing or treating cerebral amyloidosis and Alzheimer's Disease in a subject by administering to the selected subject an agent that stimulates the innate immune system. In addition, a composition useful for the stimulation of the innate immune system of a subject exhibiting symptoms associated with amyloid deposition is disclosed.
    Type: Grant
    Filed: February 20, 2009
    Date of Patent: August 20, 2019
    Assignee: New York University
    Inventors: Thomas Wisniewski, Daryl Spinner, Henrieta Scholtzova, Richard Kascsak
  • Patent number: 10377818
    Abstract: Methods of treating glioma are provided. Aspects of the invention include administering a therapeutically-effective amount of an agent that inhibits the activity of one or more neuronal activity-regulated proteins selected from: neuroligin-3, brain-derived neurotrophic factor (BDNF), or brevican, to a patient with a glioma. In certain embodiments, the subject methods involve treating a neurological dysfunction, reducing invasion of a glioma cell into brain tissue, and/or reducing the growth rate of a glioma in the patient. Also provided herein are methods for identifying an agent that modulates the mitotic index of a glial cell, and methods for stimulating the proliferation of a glial cell. Kits that find use in practicing the subject methods are also provided.
    Type: Grant
    Filed: January 29, 2016
    Date of Patent: August 13, 2019
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Michelle Monje-Deisseroth, Humsa S. Venkatesh
  • Patent number: 10358485
    Abstract: Provided herein are antibodies that specifically bind Tau and methods of using the same.
    Type: Grant
    Filed: December 12, 2018
    Date of Patent: July 23, 2019
    Assignees: Eisai R&D Management Co., Ltd., UCL Business PLC
    Inventors: Malcolm Ian Roberts, James Martin Staddon, Hettihewage Alfred Rohan De Silva, Jared Spidel, Hirofumi Aoyagi, Shigeru Akasofu, Yutaka Hashizume, Kishan Agarwala
  • Patent number: 10344065
    Abstract: A method for treating Alzheimer's disease and a method for downregulating protein aggregation in brain are disclosed, which respectively comprises: administering a zinc finger-like peptide to a subject in need thereof, wherein the zinc finger-like peptide comprises an amino acid sequence of RRSSSCK (SEQ ID NO: 1).
    Type: Grant
    Filed: March 6, 2018
    Date of Patent: July 9, 2019
    Assignee: NATIONAL CHENG KUNG UNIVERSITY
    Inventors: Nan-Shan Chang, Yu-Min Kuo
  • Patent number: 10344062
    Abstract: The present invention relates to a vaccine comprising at least one peptide consisting of 7 to 19 amino acid residues consisting of the amino acid sequence (X3)mKDX2QLGX1 (SEQ ID No. 99), wherein X1 is an amino acid residue selected from the group consisting of alanine, asparagine, glutamine, glycine, histidine, isoleucine, leucine, lysine, methionine, serine, threonine, tyrosine and valine, X2 is an amino acid residue selected from the group consisting of alanine, arginine, histidine, isoleucine, leucine, lysine, methionine, threonine, tyrosine and valine. X3 is (X4)nANISX5 (SEQ ID No. 100) or an N-terminal truncated fragment thereof consisting of 1 to 4 amino acid residues, X4 is VVASQLR (SEQ ID No.
    Type: Grant
    Filed: May 23, 2013
    Date of Patent: July 9, 2019
    Assignee: AFFIRIS AG
    Inventors: Guenther Staffler, Christine Landlinger, Frank Mattner
  • Patent number: 10335468
    Abstract: A safe and effective vaccine to prevent, slow, halt or reverse progression of Alzheimer's disease in human patients is disclosed. The vaccine includes A?1-42 or an beta amyloid self epitope (e.g. A?1-15, or other 7-mer or 15-mer peptide epitopes derived from A?1-42) conjugated to an immunogenic carrier (e.g. DT) formulated in a water-in-oil Th2-biased adjuvant/delivery system.
    Type: Grant
    Filed: October 14, 2016
    Date of Patent: July 2, 2019
    Assignee: MERCIA PHARMA, INC.
    Inventors: Peter Blackburn, Stephen Grimes
  • Patent number: 10330689
    Abstract: The present invention identifies biomarkers that are diagnostic of nerve cell injury and/or neuronal disorders. Detection of different biomarkers of the invention are also diagnostic of the degree of severity of nerve injury, the cell(s) involved in the injury, and the subcellular localization of the injury.
    Type: Grant
    Filed: November 3, 2017
    Date of Patent: June 25, 2019
    Assignees: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC., BANYAN BIOMARKERS, INC.
    Inventors: Kevin Ka-Wang Wang, Monika Oli, Ming-Cheng Liu
  • Patent number: 10323084
    Abstract: The subject invention relates to monoclonal antibodies (e.g., 8F5 and 8C5) that may be used, for example, in the prevention, treatment and diagnosis of Alzheimer's Disease or other neurodegenerative disorders.
    Type: Grant
    Filed: July 27, 2017
    Date of Patent: June 18, 2019
    Assignees: ABBVIE INC., ABBVIE DEUTSCHLAND GMBH & CO. KG
    Inventors: Heinz Hillen, Stefan Barghorn, Boris Labkovsky, Ulrich Ebert, Andreas Striebinger, Patrick Keller
  • Patent number: 10316099
    Abstract: The invention relates to a ligand capable of binding PrP at a site within amino acid residues 131 to 153 of PrP, for use in treatment or prevention of impaired synaptic plasticity. The invention also relates to a ligand capable of binding PrP at a site within amino acid residues 131 to 153 of PrP, for use in treatment or prevention of toxicity of A? oligomers. The invention also relates to a ligand capable of binding PrP at a site within amino acid residues 131 to 153 of PrP, for use in treatment or prevention of Alzheimer's Disease. The invention also relates to methods of medical treatment.
    Type: Grant
    Filed: July 8, 2016
    Date of Patent: June 11, 2019
    Assignee: D-GEN LIMITED
    Inventors: John Collinge, Andrew J Nicoll
  • Patent number: 10286092
    Abstract: The present invention relates to a method of detecting a therapeutic cell expressing a dopamine transporter (DAT) at a central nervous system (CNS) site in a subject, which comprises the administration of a DAT tracer to the subject, wherein the presence of a therapeutic cell which expresses the DAT is determined.
    Type: Grant
    Filed: August 25, 2015
    Date of Patent: May 14, 2019
    Assignee: UCL Business PLC
    Inventors: Martin Pulé, Adam Badar, Louise Kiru, Mark Lythgoe, Adrien Peters
  • Patent number: 10287346
    Abstract: The present invention aims to obtain an anti-repulsive guidance molecule a (RGMa) antibody having a high binding activity and few side effects which can be used as a medicine for preventing, treating, or preventing the relapse of neurological or immunological diseases. The problem is solved by providing an isolated RGMa binding protein which does not inhibit binding between RGMa and neogenin but neutralizes the neurite outgrowth inhibiting activity of RGMa, preferably by providing an anti-RGMa antibody which has complementarity determining regions having amino acid sequences of SEQ ID NOS: 30-35 or SEQ ID NOS: 36-40 in Sequence Listing, and SFG.
    Type: Grant
    Filed: April 27, 2016
    Date of Patent: May 14, 2019
    Assignees: MITSUBISHI TANABE PHARMA CORPORATION, OSAKA UNIVERSITY, NATIONAL UNIVERSITY CORPORATION CHIBA UNIVERSITY
    Inventors: Motonori Hashimoto, Toshihide Yamashita
  • Patent number: 10281477
    Abstract: A method of detecting the presence, or monitoring the severity of a condition characterised by the presence of fragments of a marker protein in the brain of a patient. The method comprises: (i) providing a sample comprising macrophages obtained from the patient; and (ii) detecting the presence of the marker protein or fragments thereof in the macrophages. The presence of abnormal levels of the marker protein and/or fragments thereof in the macrophages is indicative of the presence of the condition in the patient. The condition and the marker proteins can be: Alzheimer's Disease and the Abeta peptide, Parkinson's Disease and ubiquitin, Multiple Sclerosis and myelin basic protein, FrontoTemporal Dementia and tau, Amyotrophic Lateral Sclerosis and tau, Parkinson's disease, Lewy Body dementia or Alzheimer's Disease and alpha-synuclein.
    Type: Grant
    Filed: March 30, 2017
    Date of Patent: May 7, 2019
    Assignee: INVEN2 AS
    Inventors: Tormod Fladby, Lisbeth Johnsen, Kaj Blennow
  • Patent number: 10272142
    Abstract: Compositions and methods useful for the treatment of neuromyelitis optica (NMO) or neuromyelitis optica spectrum disorder (NMOSD) are disclosed.
    Type: Grant
    Filed: November 12, 2014
    Date of Patent: April 30, 2019
    Assignee: SHIRE VIROPHARMA INCORPORATED
    Inventors: Colin Broom, Jeffrey Dayno
  • Patent number: 10259877
    Abstract: The present invention relates to methods of migraine prophylaxis using anti-CGRP receptor antibodies or binding fragments. In particular, methods for preventing or reducing the occurrence of migraine headache in a patient in need thereof comprising administering to the patient an anti-CGRP receptor or binding fragment according to specific dosage regimens are disclosed. Pharmaceutical compositions and administration devices comprising anti-CGRP receptor antibodies or binding fragments for use in the methods are also described.
    Type: Grant
    Filed: April 22, 2016
    Date of Patent: April 16, 2019
    Assignee: AMGEN INC.
    Inventors: Hong Sun, Eduardo Dunayevich, Robert A. Lenz, Gabriel Vargas